Alliance A011502: A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial

Objective

This randomized phase III trial studies how well aspirin works in preventing the cancer from coming back (recurrence) in patients with human epidermal growth factor receptor 2 (HER2) breast cancer after chemotherapy, surgery, and/or radiation therapy. Aspirin is a drug that reduces pain, fever, inflammation, and blood clotting. It is also being studied in cancer prevention. Giving aspirin may reduce the rate of cancer recurrence in patients with breast cancer.

https://www.clinicaltrials.gov/ct2/show/NCT02927249

Contact Phone: 218-786-3308 | 1-844-681-7944

Email: cancertrials@essentiahealth.org

Locations: Essentia Health Cancer Centers

Disclosures:

None

For more information about a financial conflict of interest (FCOI), review the Essentia Health FCOI policy.

Last Updated: 06/04/2018

Research Study Categories

  • Adult Studies

Specialty

  • Cancer
  • Breast Cancer